Due to the stable and reliable source of API, Boshutai® has a cost advantage.

Boshutai® was successfully selected in the 13 provinces alliance procurement in 2022, which brings new opportunities for future development.

China is the world's largest diabetes country, According to the Frost & Sullivan report, in 2020, the prevalence of diabetes among Chinese adults was as high as 11.9%, and the prevalence in 2016 was 10.8%. The number of people with diabetes is expected to exceed 140 million in 2022.

Due to the late entry of new drugs such as GLP-1 receptor agonists into the Chinese market, traditional chemical oral hypoglycemic drugs still occupy the largest market share in my country's diabetes treatment drugs.